CAS 845264-92-8
:Atacicept
Description:
Atacicept is a recombinant fusion protein that acts as a therapeutic agent primarily targeting autoimmune diseases. It is designed to inhibit the activity of B cells by blocking the action of two key factors: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), both of which are crucial for B cell survival and differentiation. Atacicept is characterized by its ability to modulate the immune response, making it a candidate for treating conditions such as systemic lupus erythematosus and other autoimmune disorders. The substance is typically administered via subcutaneous injection and has undergone various clinical trials to assess its efficacy and safety profile. Its mechanism of action involves reducing the number of activated B cells and the production of autoantibodies, which are often implicated in autoimmune pathologies. As with any therapeutic protein, considerations regarding immunogenicity, pharmacokinetics, and potential side effects are essential in its development and application.
Formula:Unspecified
Synonyms:- Atacicept
- TACI-Fc 5
- Glycoprotein TACI-Fc5 (synthetic human)
- TACI-Ig
- Cytokine receptor TACI (synthetic human extracellular domain fragment) fusion protein with immunoglobulin G1 (synthetic human γ1-chain Fc fragment), dimer
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Atacicept
CAS:<p>Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B cell stimulation.</p>Purity:97.9% (SDS-PAGE); 98.7% (SEC-HPLC) - 97.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:Liquid
